Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Recurrent or Metastatic Breast Cancer

In brief

The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.

Key facts

Study ID
NCT03326102
Run by
Daehwa Pharmaceutical Co., Ltd.
People needed
72
Starts
2018-07-06
Expected to finish
2022-12-13
Last updated by the study team
2024-02-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.